Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.44 |
| ▸ | PTGES | O14684 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905826 | 0.94 | LMNA (0.61) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4899995 | 0.91 | LMNA (0.58) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4899425 | 0.91 | LMNA (0.58) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4906197 | 0.90 | LMNA (0.51) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4907519 | 0.89 | LMNA (0.54) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4906805 | 0.89 | LMNA (0.56) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4902654 | 0.88 | LMNA (0.61) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4903420 | 0.86 | LMNA (0.57) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4895112 | 0.86 | LMNA (0.59) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4907142 | 0.86 | HCRTR2 (0.54) | LMNAALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765796-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | claimed |
| WO-2006003495-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| EP-1994015-B1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | FELSTEAD STEPHEN JOHN | 2010-10-21 | — | — | US | disclosed |
| WO-2009027785-A2 | 1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1994015-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2007107843-A1 | METHODS OF TREATMENT WITH CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007105049-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| WO-2006109170-A2 | COMBINATION THERAPY FOR TREATMENT OF CARDIOVASCULAR DISEASES AND RELATED CONDITIONS | ESPERION THERAPEUTICS INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | LMNA 317/4885ALDH1A1 2664/4885HPGD 696/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | LMNA 319/4885ALDH1A1 2956/4885HPGD 724/4885 |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | LMNA 584/4885ALDH1A1 1853/4885HPGD 1222/4885 |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | LMNA 584/4885ALDH1A1 1853/4885HPGD 1222/4885 |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | CETP, CCR5, MTTP | LMNA 2316/4885ALDH1A1 2908/4885HPGD 839/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885ALDH1A1 2956/4885HPGD 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.